Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab
Theratechnologies Inc. today announced 48-week efficacy and safety results for ibalizumab in patients infected with multidrug resistant HIV-1, Marketwired reports.
"As we await an FDA decision for ibalizumab, this long-term data reinforces the critical role ibalizumab could have for patients struggling with multidrug resistant HIV," said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc. "With the dramatic progress made over the past two decades in treating HIV, the crucial need for new treatments for these very vulnerable patients is often overlooked."
Ibalizumab is an investigational humanized monoclonal antibody being developed for the treatment of multidrug resistant HIV-1 infection. Ibalizumab is currently under accelerated review by the FDA following the acceptance of a Biologics License Application on June 30, 2017. The FDA target action date to complete the review of ibalizumab is January 3, 2018.